Oslo, Norway, January 11, 2022 – PCI Biotech (OSE: PCIB), a cancer-focused biopharmaceutical company, today announced that the results of preclinical tuberculosis studies conducted in collaboration with the University of Zurich and ETH Zurich are accepted for publication in Frontiers in Immunology, a high-impact immunology journal. The title of the article is “Photochemically-mediated inflammation and protein cross-presentation of Mycobacterium bovis BCG stimulates strong CD4 and CD8 T cell responses in mice” and the summary of the publication is available via this link: www.frontiersin .org / articles / 10.3389 / fimmu.2022.815609 / abstract.
Anders Høgset, CSO of PCI Biotech, comments: “Infectious diseases are not among PCI Biotech’s main focus areas, but these positive results support our general understanding of fima.Vaccthe mode of action of and further demonstrate the vast potential of the technology.
By Walday, CEO
Mobile: +47 917 93 429
About PCI Biotech
PCI Biotech is an advanced-stage biopharmaceutical clinical development company focused on the development and commercialization of novel therapies for the treatment of cancer through its innovative photochemical internalization (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChemistry (reinforcement of chemotherapy for the localized treatment of cancer), fimaVacc (T cell induction technology for therapeutic vaccination), and fimaNAc (administration of therapeutic nucleic acids).
Photochemical internalization induces triggered endosomal release which is used to unleash the true potential of a wide range of therapeutic modalities. The company’s flagship program fimaChemistry is a pivotal study in bile duct cancer, an orphan indication with a high unmet need and no approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works synergistically with several other advanced vaccination technologies. fimaNAc uses endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapies, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For more information, please visit: www.pcibiotech.com
This announcement may contain forward-looking statements, which as such are not historical facts, but are based on various assumptions, many of which are, in turn, based on other assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other significant factors. These risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by these forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.